Merrimack Pharmaceuticals Initiates enrollment in a Phase 2 study of MM-093 in patients with rheumatoid arthritis
Merrimack Pharmaceuticals, Inc. today announced the launch of a phase 2 study to evaluate the safety and efficacy of its immunomodulator, MM-093 in patients with rheumatoid arthritis (RA). MM-093, Merrimacks flagship product, is a recombinant version of alpha-fetoprotein (AFP). The randomized, double-blind, placebo-controlled, phase 2 study was conducted in 15 centers in the United States.approximately 90 100 patients with moderate to severe active rheumatoid arthritis despite stable doses of methotrexate. Each patient receives 60 mg of MM-093 or placebo weekly for 12 weeks with 4 weeks. In addition to assessing the safety of MM-093, patients are due to changes in the signs and symptoms of the disease with standard measures of clinical course of RA, such as ACR20 and DAS28
to assess results.profile is unique to distinguish it from other therapies and allow it to make a significant difference in the competitive market to RA, said Robert Mulroy, President CEO of Merrimack. Despite advances in the treatment of signs and symptoms of RA was made, there remains a need for security, effective therapies. This study follows an exploratory phase 2, dose-ranging study of MM-093 in patients with RA completed in 2006.
The trial at the European League Against Rheumatism (EULAR) in Barcelona this spring. MM-093 also completed a phase of a study in healthy volunteers and in a pilot study in patients with RA proved to be well tolerated and biologically active in the treatment of signs and symptoms of RA. Merrimack control an area of ​​strong
intellectual property around MM-093, including 14 patents and a number of pending applications, both in the U.S.Methods and therapeutic uses of the drug. Merrimack Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing new treatments for diseases in the areas of autoimmune diseases and cancer. Its flagship product, the MM-093, is currently in clinical development to treat patients with
Pages: [1] 2